Related Experiment Video
Updated: May 16, 2026
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Optimizing response to gefitinib in the treatment of non-small-cell lung cancer
Pietro Carotenuto1, Cristin Roma, Anna Maria Rachiglio
1Pharmacogenomic Laboratory, CROM - Centro Ricerche Oncologiche di Mercogliano, Avellino, Italy;
Abstract:
The epidermal growth factor receptor (EGFR) is expressed in the majority of non-small-cell lung cancer (NSCLC). However, only a restricted subgroup of NSCLC patients respond to treatment with the EGFR tyrosine kinase inhibitor (EGFR TKI) gefitinib. Clinical trials have demonstrated that patients carrying activating mutations of the EGFR significantly benefit from treatment with gefitinib. In particular, mutations of the EGFR TK domain have been shown to increase the sensitivity of the EGFR to exogenous growth factors and, at the same time, to EGFR TKIs such as gefitinib. EGFR mutations are more frequent in patients with particular clinical and pathological features such as female sex, nonsmoker status, adenocarcinoma histology, and East Asian ethnicity. A close correlation was found between EGFR mutations and response to gefitinib in NSCLC patients. More importantly, randomized Phase III studies have shown the superiority of gefitinib compared with chemotherapy in EGFR mutant patients in the first-line setting. In addition, gefitinib showed a good toxicity profile with an incidence of adverse events that was significantly lower compared with chemotherapy. Therefore, gefitinib is a major breakthrough for the management of EGFR mutant NSCLC patients and represents the first step toward personalized treatment of NSCLC.
Insights
Activating mutations in the epidermal growth factor receptor (EGFR) predict a significant benefit from gefitinib treatment in non-small-cell lung cancer (NSCLC). This EGFR TKI offers superior efficacy and a better safety profile than chemotherapy for EGFR-mutated NSCLC patients.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacogenomics
Background:
- Epidermal growth factor receptor (EGFR) is frequently expressed in non-small-cell lung cancer (NSCLC).
- Response to EGFR tyrosine kinase inhibitors (TKIs) like gefitinib is limited to a subset of NSCLC patients.
- EGFR mutations are linked to specific clinical and pathological features, including female sex, non-smoker status, adenocarcinoma histology, and East Asian ethnicity.
Purpose of the Study:
- To investigate the correlation between EGFR mutations and gefitinib response in NSCLC.
- To evaluate the efficacy and safety of gefitinib compared to chemotherapy in EGFR-mutated NSCLC patients.
- To establish gefitinib as a personalized treatment for NSCLC.
Main Methods:
- Analysis of clinical trial data for NSCLC patients treated with gefitinib.
- Comparison of gefitinib versus chemotherapy in randomized Phase III studies.
- Assessment of EGFR mutation status and its association with treatment outcomes and toxicity.
Main Results:
- Activating EGFR mutations significantly correlate with response to gefitinib in NSCLC.
- Gefitinib demonstrates superiority over chemotherapy in the first-line treatment of EGFR-mutant NSCLC.
- Gefitinib exhibits a favorable toxicity profile with fewer adverse events compared to chemotherapy.
Conclusions:
- EGFR mutations are a key predictive biomarker for gefitinib efficacy in NSCLC.
- Gefitinib represents a breakthrough therapy for EGFR-mutant NSCLC, enabling personalized treatment strategies.
- The findings support the use of gefitinib as a first-line treatment for patients with EGFR-mutated NSCLC.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase